[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Sao Paulo\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":742},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,76,0,25,[9,40,71,94,120,147,179,202,234,264,294,319,351,389,416,444,468,488,513,559,588,613,667,690,716],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100652454","platelets-and-plasma-lipids-relationship-as-a-biomarker-and-potential-therapeutic-target-of-thrombogenesis-100652454",false,"NCT07774845","Platelets and Plasma Lipids Relationship as a Biomarker and Potential Therapeutic Target of Thrombogenesis","Development and Validation of a New Method to Valuate the Platelet-Plasma Lipid Relationship as a Biomarker and Potential Therapeutic Target of Thrombogenesis","Inclusion Criteria:\n\n* Men and women aged ≥ 40 years.\n* Willingness to sign the informed consent form.\n* Absence of known atherosclerotic disease\n\nExclusion Criteria:\n\n* Use of antiplatelet agents.\n* Use of anticoagulants.\n* Use of lipid-lowering agents.\n* Use of oral hypoglycemic agents or insulin.\n* Known atherosclerotic disease.\n* Refusal to sign the informed consent form",true,"ALL","40 Years",{"count":21,"type":22},45,"ESTIMATED","OBSERVATIONAL","The objective of this clinical trial is to compare the effect of two different lipid emulsion formulations versus no emulsion on platelet aggregation in individuals without a history of ischemic disease. The hypothesis of this study is:\n\nPlatelet aggregation is inversely associated with higher plasma lipid concentrations.\n\nThe researchers will compare platelet aggregation in the presence and absence of lipid nanoemulsions in vitro through three pathways using the agonists collagen, adenosine diphosphate, and arachidonic acid. The tests will be performed using light-transmission aggregometry. Various participant parameters, such as lipid profile, will be evaluated to analyze possible correlations with the observed results.\n\nParticipants must:\n\nMeet the study's inclusion criteria; Sign the informed consent form; Report to the blood draw laboratory at InCor's AB on the scheduled date and time after fasting for at least 8 hours.",[26],"Cardio Vascular Disease","RECRUITING","2026-08-17",{"date":30,"type":31},"2026-08-19","ACTUAL",{"date":33,"type":31},"2026-03-05",{"date":35,"type":22},"2026-11",{"name":37,"class":38},"University of Sao Paulo","OTHER",1,{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":39},"100651631","periodontal-tissue-stability-after-surgical-correction-of-altered-passive-eruption-100651631","NCT07762482","Periodontal Tissue Stability After Surgical Correction of Altered Passive Eruption","Analysis of Periodontal Tissue Stability After Surgical Correction of Altered Passive Eruption in Individuals With Excessive Gingival Display","Inclusion Criteria:\n\n* Adults with an esthetic complaint related to excessive gingival display.\n* Diagnosis of altered passive eruption as one of the etiologic factors associated with excessive gingival display.\n* Altered passive eruption involving the alveolar bone.\n\nExclusion Criteria:\n\n* Current orthodontic treatment.\n* Active periodontal disease.\n* Systemic conditions that contraindicate periodontal surgical procedures, including uncontrolled autoimmune diseases.\n* Use of medications that may interfere with the inflammatory response or wound healing, including corticosteroids or immunosuppressive agents.\n* Current smokers.\n* Former smokers who discontinued smoking less than 12 months before enrollment.\n* Pregnant or breastfeeding individuals.\n* Excessive gingival display primarily associated with lip hypermobility or vertical maxillary excess without concomitant altered passive eruption.","18 Years",{"count":49,"type":22},10,"INTERVENTIONAL",[52],"NA","This prospective, single-group interventional study will evaluate the stability of periodontal tissues after esthetic periodontal surgery for the correction of altered passive eruption in individuals with excessive gingival display. Ten adult participants with excessive gingival display associated with altered passive eruption and involvement of the alveolar bone will be included.\n\nParticipants will undergo esthetic crown-lengthening surgery consisting of gingivectomy and osseous recontouring. Periodontal clinical measurements, intraoral digital scans, cone-beam computed tomography, standardized photographs, and patient-reported outcomes will be obtained before surgery and during follow-up. Clinical and three-dimensional tissue changes, esthetic perception, satisfaction, and oral health-related quality of life will be evaluated for up to 12 months after treatment.",[55],"Altered Passive Eruption",[57,58,59,60,61,62,63],"Gummy Smile","Esthetic Crown Lengthening","Gingivectomy","Osseous Surgery","Periodontal Plastic Surgery","Periodontal Tissue Stability","Intraoral Scanning","2026-08-12",{"date":28,"type":31},{"date":67,"type":31},"2026-08-10",{"date":69,"type":22},"2028-02",{"name":37,"class":38},{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":50,"phases":80,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":39},"100650489","phase-1-effects-of-a-sigle-dose-of-ayahuasca-in-patients-with-psychogenic-non-epileptic-seizures-an-open-label-clinical-trial-100650489","NCT07747324","Effects of a Sigle Dose of Ayahuasca in Patients With Psychogenic Non-epileptic Seizures: an Open Label Clinical Trial","Inclusion Criteria:\n\n* Patients aged 18 to 60 with documented PNES (confirmed via VEEG), without a diagnosis of comorbid epilepsy, and currently receiving follow-up care at outpatient clinics. To enroll in the study, patients must undergo a gradual reduction and discontinuation of any psychotropic medications (antidepressants, antipsychotics, benzodiazepines, or mood stabilizers\u002Fanticonvulsants) they are currently taking, in order to avoid drug interactions with-or influence on-the effects of ayahuasca.\n\nExclusion Criteria:\n\n* Patients who have not experienced psychogenic seizures in the last 3 months; patients diagnosed with epilepsy; patients who refuse to reduce or discontinue their current psychotropic medications; patients with a history of prior ayahuasca use; patients with a history of substance use disorder; patients who refuse to sign the Informed Consent Form; patients with schizophrenia or other psychotic disorders and\u002For impaired reality testing; and pregnant or breastfeeding women.","60 Years",{"count":79,"type":22},15,[81,82],"PHASE1","PHASE2","Open label intervention with a single dose of ayahuasca in patients with psychogenic non-epileptic seizures (PNES)",[85],"Non Epileptic Seizures","2026-07-30",{"date":88,"type":31},"2026-08-05",{"date":90,"type":31},"2026-07-01",{"date":92,"type":22},"2027-08-30",{"name":37,"class":38},{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":77,"enrollmentInfo":101,"targetDuration":4,"studyType":50,"phases":103,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":117,"leadSponsor":119,"locationsCount":39},"100412387","phase-2-predicting-response-to-naltrexone-with-eye-tracking-in-gaming-disorder-100412387","NCT04649892","Predicting Response to Naltrexone With Eye Tracking in Gaming Disorder","Predicting Response to Naltrexone With Eye Tracking in Videogame Disorder","Inclusion Criteria:\n\n* Patients will be evaluated initially in a clinical interview by a specialized psychiatrist and then by a second interviewer who will use a semi-structured interview to check the DSM-5 criteria for Video Game Disorder (VGD) modeled in the standard format of Schedules for clinical assessment in neuropsychiatry (SCID). Only a specific subgroup of VGD will be included in our sample, which will be called VGDa, a sample that represent a framework of behavioral dependence in essence. Patients in this sample must necessarily have the following symptoms: salience, withdrawal, relapse, conflict, mood modification and fissure. The criteria to delimit this subgroup are listed below:\n* Patients diagnosed with Internet Gaming Disorder according to DSM-5\n* Patients who have a score of 4 or higher on the following questions on the IGDS9-SF scale (Internet Gaming Disorder Scale 9 - Short Form):\n\nQuestion 1: Salience assessment. Question 2: Abstinence assessment. Question 4: Relapse assessment. Question 6: Conflict assessment. Question 8: Mood modification assessment.\n\n* Patients with craving according to the adaptation of the Gambling Follow-up Scale (GFS) described below.\n\nAn adaptation of the GFS scale, originally used to evaluate patients with Gambling Disorder, was made in order to allow the evaluation of the craving symptom in a patient with VGD. It will only be used the fourth question on this scale as follows.\n\n\"4) In the past 4 weeks, how was your desire to play?\n\n1. I felt an irresistible urge to play.\n2. I felt a strong desire to play, sometimes resistable, sometimes not.\n3. I felt a strong desire to play, but resistable most of the time.\n4. I felt a slight desire to play.\n5. I didn't feel like playing. \" It will considered that the patient has craving if he answers this question by selecting items 1, 2 or 3.\n\nPatients must meet the following criteria before randomization:\n\n* Have read and signed the informed consent form after the nature of the study has been fully explained and before carrying out any procedures related to the study;\n* Age between 18 and 60 years old, inclusive;\n* Female patients must be:\n\n  1. In post-menopause for at least one year, or;\n  2. Being surgically incapable of becoming pregnant (undergoing bilateral hysterectomy or oophorectomy or tubal ligation or otherwise being unable to become pregnant), or;\n  3. Be practicing an acceptable method of birth control (defined as: hormonal contraceptives, spermicide plus barrier, a single vasectomized partner and \u002F or intrauterine device).\n  4. If a patient with the potential to become pregnant is practicing an acceptable method of birth control (as mentioned above), she must have a negative urine pregnancy test at the enrollment stage, as well as, at baseline, before receiving the study drug.\n\nExclusion Criteria:\n\n* \\- Established contraindication to naltrexone (opioid dependence, in the process of opioid withdrawal or current use of opioid analgesics) or hypersensitivity to naltrexone;\n* Exposure to any other drug or experimental device in the 30 days prior to inclusion, except for occasional use of benzodiazepines;\n* Pregnancy, breastfeeding or patients who intend to become pregnant during the study;\n* Evidence of renal failure, defined as serum creatinine levels\\> 133 mmol \u002F L in men and\\> 124 mmol \u002F L in women, which correspond to\\> 1.51 mg \u002F dl and\\> 1.41 mg \u002F dl, respectively on Week 1 of inclusion;\n* Evidence of clinically significant liver failure (defined as AST or ALT\\> 2 times the upper limit of normal) in Week 1 of inclusion;\n* Significant cardiovascular disease, including a history of myocardial infarction in the last 5 years, stroke, clinically significant heart valve disease, unstable angina, clinically abnormal ECG, arrhythmia or congestive heart failure, determining functional class III or IV (NYHA, 1964);\n* Uncontrolled hypertension (defined as a diastolic blood pressure of 100 mm \u002F Hg and \u002F or a systolic blood pressure of 180 mm \u002F Hg with or without medication). Hypertensive patients receiving medication should be receiving the same dose of the same antihypertensive medication for at least two months;\n* Evidence of uncontrolled thyroid disorders, including hyper or hypothyroidism or abnormal TSH level. Patients who are known to have thyroid hormone replacement need to have had a stable dose for at least three months prior to inclusion and a normal TSH level upon inclusion\n* History or current comorbidity with bipolar affective disorder, obsessive compulsive disorder, psychotic disorder, schizophrenia or severe depression, additionally verified through the Patient Health Questionnaire 9 (PQH-9\\> 19), current suicide risk, or any other neuropsychiatric condition in severe cognitive impairment;\n* Current or previous history (in the previous two years) of abuse \u002F dependence on alcohol or other psychoactive substance (except nicotine);\n* If at any moment the clinician responsible for the patient identifies suicidal ideation with risk of self-harm, or death;\n* Clinically significant hematological or immunological disorder;\n* Patients currently receiving psychotropic medications, except for the episodic use of benzodiazepines;\n* Illiteracy, or any other condition that prevents the reading and understanding of the research instruments;\n* Do not have a telephone line available for remote monitoring;\n* Living alone, or not being able to present a family member capable of providing collateral information on gaming behavior;\n* To be followed up in another therapeutic program.\n\nThe Mini International Neuropsychiatric Interview (MINI) will be used to verify the psychiatric exclusion diagnoses. This is a structured diagnostic interview, with quick application - approximately 45 minutes - compatible with the DSM-IV criteria. Its objective is the verification and standardization of the main Psychiatric Disorders of Axis 1 of DSM IV. It is performed by clinicians after rapid training (1 to 3 hours). The translated and adapted Brazilian version showed globally satisfactory reliability.",{"count":102,"type":22},40,[82],"It is a double blind controlled study to test the hypothesis that it's possible to predict the response to naltrexone in Videogame Disorder with the use of Eye Tracking device, during a period of 12 weeks",[106],"Gaming Disorder",[108,109,110,111,112],"Videogame disorder","Gaming disorder","eye tracking","naltrexone","problematic videogame users","2026-07-23",{"date":115,"type":31},"2026-07-27",{"date":90,"type":31},{"date":118,"type":22},"2027-07",{"name":37,"class":38},{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":129,"conditions":130,"keywords":133,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":4},"100648952","diagnostic-accuracy-and-operational-efficiency-of-point-of-care-ultrasound-pocus-in-long-bone-fractures-a-brazilian-multicenter-study-100648952","NCT07728227","Diagnostic Accuracy and Operational Efficiency of Point-of-Care Ultrasound (POCUS) in Long Bone Fractures: A Brazilian Multicenter Study","POCUS-BONE BR","Inclusion Criteria:\n\n* Patients aged 18 years or older;\n* Presenting with clinical suspicion of a long bone fracture (pain, deformity, swelling, or functional limitation);\n* Provision of informed consent (signed Informed Consent Form - ICF).\n\nExclusion Criteria:\n\n* Patients with open fractures;\n* Hemodynamic instability (resuscitation priority);\n* Known previous fractures in the same bone segment;\n* Need for immediate surgical intervention;\n* Refusal to participate.",{"count":128,"type":22},260,"The purpose of this study is to evaluate the diagnostic accuracy and operational efficiency of Point-of-Care Ultrasound (POCUS) for identifying long bone fractures in the emergency department.\n\nTraditionally, suspected long bone fractures are diagnosed using X-rays. While effective, X-rays require transporting patients to a radiology suite, involve exposure to ionizing radiation, and can contribute to longer emergency room wait times. POCUS is a portable, radiation-free imaging tool that physicians perform directly at the patient's bedside. The investigators hypothesize that POCUS can accurately identify or rule out long bone fractures when compared to standard X-rays, and that its use will reduce the time required to make clinical decisions.\n\nThis is a multicenter, prospective observational study. Participants arriving at the emergency department with a suspected long bone fracture will undergo a bedside ultrasound examination performed by a trained emergency physician. Following the ultrasound, all participants will receive standard-of-care X-ray imaging.\n\nResearchers will compare the initial POCUS findings to the final X-ray results (the reference standard) to determine the sensitivity and specificity of the ultrasound. Additionally, the study will measure operational timelines-including time to diagnosis, time to treatment decision, and total length of stay in the emergency department-to assess the impact of POCUS on hospital workflow and patient care efficiency.",[131,132],"Bone Fractures","Long Bone Fracture",[134,135,136,137,138],"POCUS","Ultrassound","Fractures","Bones","POCUS BONES BR","NOT_YET_RECRUITING","2026-07-21",{"date":115,"type":31},{"date":143,"type":22},"2026-10-19",{"date":145,"type":22},"2027-11-20",{"name":37,"class":38},{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":17,"sex":155,"minAge":77,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":50,"phases":159,"briefSummary":160,"conditions":161,"keywords":165,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100647733","plasma-taurine-in-older-women-with-obesity-impact-of-metabolic-phenotype-and-combined-exercise-100647733","NCT07711899","Plasma Taurine in Older Women With Obesity: Impact of Metabolic Phenotype and Combined Exercise","Plasma Taurine Concentrations in Older Women With Obesity: The Influence of Metabolic Phenotype and Combined Exercise Training","non applicable","Inclusion Criteria\n\n* Women aged 60 to 75 years.\n* Residents of the city or region of Ribeirão Preto, São Paulo, Brazil.\n* Physically inactive for at least 3 months.\n* Body mass index (BMI) ≥ 30 kg\u002Fm² (PAHO, 2002).\n* Body fat percentage ≥ 35%, according to obesity diagnostic criteria (Batsis et al., 2016; Rubino et al., 2025).\n\nClassified into one of two obesity phenotypes based on Zembic et al. (2021):\n\nMetabolically Healthy Obesity (MHO\u002FOMS): all of the following criteria must be met:\n\n* Systolic blood pressure (SBP) \\\u003C 130 mmHg;\n* Waist-to-hip ratio \\\u003C 0.95;\n* Fasting blood glucose \\\u003C 126 mg\u002FdL.\n\nMetabolically Unhealthy Obesity (MUO\u002FOMNS): meets two or fewer of the above criteria.\n\nExclusion Criteria\n\nClinical conditions\n\n* Contraindication to physical exercise.\n* Current or previous diagnosis of:\n\n  * Neoplasms;\n  * Autoimmune diseases;\n  * Hepatic diseases;\n  * Coronary diseases;\n  * Renal diseases;\n  * Neurodegenerative diseases;\n  * Infectious diseases.\n\nPrevious or ongoing treatments\n\n* Use of medication for thyroid disorders.\n* Participation in exercise training programs, nutritional counseling, or weight loss treatment within the 3 months preceding the intervention.\n\nLifestyle habits\n\n* Current smoking.\n* Alcohol consumption.\n\nFor MHO Group:\n\n* Medication use\n\n  * Hypoglycemic agents\n  * Insulin (Bell, Kivimäki, \\& Hamer, 2014).\n* Protocol adherence \\*Attendance at less than 80% of the training sessions (De Carvalho et al., 2021).","FEMALE","75 Years",{"count":158,"type":22},36,[52],"Population aging has been accompanied by a rise in obesity and other chronic diseases, increasing cardiovascular risk particularly among women, who exhibit a higher prevalence in older age groups compared to men. Aging and obesity share pathophysiological mechanisms, such as chronic inflammation and oxidative stress. However, distinct obesity phenotypes exist, such as metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO). Consequently, therapeutic interventions involving nutritional strategies and physical training are highly relevant, especially for older women. Taurine, a sulfur-containing amino acid, plays a role in modulating oxidative stress, inflammation, osmoregulation, and mitochondrial function. Rationale: Plasma taurine concentrations are lower in women with obesity compared to healthy individuals. However, studies investigating these concentrations across different phenotypes-particularly in older women, a group susceptible to functional and metabolic changes-remain limited. Understanding these variations could clarify taurine's role in the pathophysiology of obesity and aging and inform personalized therapeutic strategies. Combined physical training stands out as an effective strategy for modulating inflammatory, oxidative, and metabolic pathways, in addition to improving psychosocial aspects. Given that taurine levels can be influenced by these pathways, investigating the taurine response to physical training across different metabolic phenotypes may contribute to developing low-cost interventions aimed at improving the quality of life for older women with obesity.",[162,163,164],"Obesity (BMI>30)","Metabolically Healthy Obesity","Metabolically Unhealty Obese",[166,167,168,169,170],"Taurine","Metabolically unhealthy obesity.","Metabolically healthy obesity.","Physical training","Aging","2026-07-16",{"date":173,"type":31},"2026-07-20",{"date":175,"type":22},"2026-10-01",{"date":177,"type":22},"2030-03-01",{"name":37,"class":38},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":17,"sex":155,"minAge":47,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":50,"phases":190,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":4},"100623189","omega-3-supplementation-in-systemic-lupus-erythematosus-100623189","NCT07393399","Omega-3 Supplementation in Systemic Lupus Erythematosus","Omega-3 Supplementation in Women With Systemic Lupus Erythematosus: Protocol for a Randomized, Double-blind, Placebo-controlled Trial","SLE-OMEGA","Inclusion Criteria:\n\n* Women aged 18 to 45 years\n* Diagnosis of systemic lupus erythematosus (SLE) according to the EULAR\u002FACR classification criteria\n* Remission or low disease activity, defined as SLEDAI-2K ≤ 4\n* On stable doses of hydroxychloroquine and\u002For glucocorticoids (≤10 mg\u002Fday of prednisone or equivalent) for at least 8 weeks prior to enrollment\n* Ability and willingness to provide written informed consent\n* Willingness to maintain usual dietary patterns and physical activity levels throughout the study period\n\nExclusion Criteria:\n\n* Current use of omega-3 fatty acid supplements or use within the previous 3 months\n* Pregnancy or lactation\n* Presence of severe infection, neoplastic disease, or diabetes mellitus\n* Known allergy or intolerance to fish oil or soybean oil\n* Any medical condition or circumstance that, in the investigator's opinion, could interfere with study participation or adherence to the protocol","45 Years",{"count":189,"type":22},80,[52],"This randomized, double-blind, placebo-controlled clinical trial aims to evaluate whether oral omega-3 fatty acid supplementation can modulate inflammation, oxidative stress, and telomere maintenance in women with systemic lupus erythematosus (SLE) in remission. Women aged 18-45 years with SLE (SLEDAI-2K ≤ 4) will be allocated to receive either omega-3 (5,400 mg\u002Fday of EPA+DHA) or placebo for 12 weeks. A parallel healthy control group will undergo the same intervention scheme. Clinical, biochemical, and molecular assessments including inflammatory cytokines, oxidative stress markers (TBARS, ORAC, T-AOC), and relative telomere length (T\u002FS ratio) will be conducted at baseline and post-intervention. The trial is designed to determine whether omega-3 can attenuate chronic low-grade inflammation and oxidative imbalance, both key drivers of cellular dysfunction and premature immunosenescence in SLE. Omega-3 PUFAs exert anti-inflammatory effects through competition with arachidonic acid for COX\u002FLOX enzymes and by activating GPR120, which inhibits the TAK1-NF-κB-JNK inflammatory cascade. Their antioxidant effects may further reduce reactive oxygen species and support genomic stability. By integrating clinical, biochemical, and molecular outcomes, this study provides a comprehensive evaluation of omega-3 effects on pathways implicated in accelerated cellular aging in autoimmune diseases. The findings are expected to clarify whether omega-3 supplementation represents a safe, low-cost strategy capable of improving inflammatory and oxidative profiles and contributing to telomere preservation in women with SLE, supporting future precision-nutrition approaches in this population.",[193],"Lupus Erythematosus, Systemic","2026-07-15",{"date":196,"type":31},"2026-07-17",{"date":198,"type":22},"2026-07",{"date":200,"type":22},"2028-07",{"name":37,"class":38},{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":17,"sex":18,"minAge":209,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":50,"phases":212,"briefSummary":213,"conditions":214,"keywords":220,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":39},"100595983","harm-reduction-intervention-for-anabolic-androgenic-steroids-users-a-randomized-controlled-trial-100595983","NCT07039539","Harm Reduction Intervention for Anabolic-androgenic Steroids Users: a Randomized Controlled Trial","SOS-RCT-HR","Inclusion Criteria:\n\n* Anyone over 15 years of age;\n* Planning to use\u002Fincrease the dose of AAS for aesthetic and\u002For physical performance purposes;\n* Plan to use\u002Fincrease the dose of AAS during eight to twelve weeks.\n\nExclusion Criteria:\n\n* Medical prescription for AAS use;\n* Use for sexual reassignment.","15 Years",{"count":211,"type":22},32,[52],"This clinical trial aims to investigate the short and long-term efficacy of a harm reduction intervention in reducing the use of non-clinical anabolic-androgenic steroids (AAS) in abusive users of AAS. As secondary objectives, the study will investigate the intervention's effect on health parameters (i.e., blood), quality of life, sleep quality, body image, eating behavior, depression, anxiety, fatigue, aggressiveness, cardiovascular parameters, muscle strength, body composition and muscle cross-sectional area outcomes.",[215,216,217,218,219],"Drug Abuse","Harm Reduction","Minimization, Harm","Anabolic Steroids Adverse Events","Brief Intervention",[221,222,223,224,225,226,219],"human enhancement drug","performance and image enhancement drug","anabolic androgenic steroids","drug consumption","doping","harm reduction","2026-07-14",{"date":171,"type":31},{"date":230,"type":22},"2026-08-01",{"date":232,"type":22},"2028-01-30",{"name":37,"class":38},{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":77,"enrollmentInfo":241,"targetDuration":4,"studyType":50,"phases":242,"briefSummary":243,"conditions":244,"keywords":249,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":261,"leadSponsor":263,"locationsCount":4},"100647312","clinical-and-histological-evaluation-of-subepithelial-connective-tissue-graft-maturation-at-different-healing-timepoints-with-and-without-topical-application-of-a-polynucleotide--and-hyaluronic-acid-based-gel-100647312","NCT07708051","Clinical and Histological Evaluation of Subepithelial Connective Tissue Graft Maturation at Different Healing Timepoints, With and Without Topical Application of a Polynucleotide- and Hyaluronic Acid-Based Gel","Clinical and Histological Evaluation of Subepithelial Connective Tissue Graft Maturation at Different Healing Timepoints, With and Without Topical Application of a Polynucleotide- and Hyaluronic Acid-Based Gel: A Randomized, Blinded, Controlled Clinical Trial With a Split-Mouth Design","Inclusion Criteria:\n\n* Age between 18 and 60 years\n* Good general systemic health\n* Presence of multiple bilateral gingival recessions with indication for root coverage\n\nExclusion Criteria:\n\n* Smoking of any intensity\n* Pregnancy or lactation\n* Oral lesions or alterations in the palatal mucosa\n* Previous history of graft harvesting from the donor area\n* Continuous use of medications that interfere with the inflammatory response, such as corticosteroids or immunosuppressants\n* Autoimmune diseases, coagulation disorders, or other systemic conditions affecting wound healing",{"count":79,"type":22},[52],"This study evaluates whether a 9-week healing interval is sufficient for subepithelial connective tissue graft (SCTG) maturation after palatal harvesting, and whether topical application of a polynucleotide and hyaluronic acid gel (Regenfast®) improves tissue quality. This is a randomized, blinded, controlled clinical trial with a split-mouth design involving 15 participants. Each participant undergoes bilateral SCTG harvesting from the palate in two surgical sessions 9 weeks apart. In the first session, one randomized side receives a single topical application of Regenfast® after graft removal; the contralateral side serves as control. Standardized tissue fragments (3×3 mm, 1.5 mm thickness) are collected from each graft for histological (HE, Picrosirius Red) and immunohistochemical analyses. Comparisons are made between grafts collected at baseline and after 9 weeks, and between sides treated with or without the gel.",[245,246,247,248],"Gingival Recession, Generalized","Gingival Recession, Localized","Wound Healing","Palate; Wound",[250,251,252,253,254,255,256,257],"Subepithelial connective tissue graft","Palatal donor site","Wound healing","Gingival Recession","Hyaluronic acid","Polynucleotides","Split-mouth clinical trial","Histological analysis","2026-07-13",{"date":171,"type":31},{"date":198,"type":22},{"date":262,"type":22},"2027-02-27",{"name":37,"class":38},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":50,"phases":275,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":291,"leadSponsor":293,"locationsCount":39},"100646961","respiratory-physiotherapy-and-hospitalization-in-infants-with-bronchiolitis-100646961","NCT07682844","Respiratory Physiotherapy and Hospitalization in Infants With Bronchiolitis","Impact of Outpatient Respiratory Physiotherapy on Hospitalizations and Costs in Infants With Acute Viral Bronchiolitis: A Quasi-Experimental Study in Public Health Services in Sorocaba.","BVA-RESP","Inclusion Criteria:\n\n* Infants aged 12 months or younger.\n* Clinical diagnosis of acute viral bronchiolitis.\n* Mild or moderate bronchiolitis according to clinical assessment and Wang Bronchiolitis Severity Score.\n* Initial evaluation performed at a participating emergency care unit (UPA).\n* Parent or legal guardian able and willing to provide informed consent for participants receiving direct physiotherapy care.\n\nExclusion Criteria:\n\n* Severe bronchiolitis requiring immediate hospitalization or emergency medical intervention.\n* Infants who did not follow the predefined clinical care pathway (e.g., no initial evaluation at a participating emergency care unit).\n* Absence of a clinical diagnosis of acute viral bronchiolitis by the attending pediatrician.\n* Any medical condition that, in the opinion of the clinical team, would make participation inappropriate or interfere with study procedures.","12 Months",{"count":274,"type":22},1000,[52],"Acute Viral Bronchiolitis (AVB) is one of the leading causes of respiratory illness and hospitalization among infants during the first year of life, generating a substantial burden on healthcare services and public health expenditures. Despite the widespread use of respiratory physiotherapy in clinical practice, there is limited evidence regarding its effectiveness in preventing hospital admissions when provided in an outpatient setting.\n\nThis quasi-experimental study aims to evaluate the impact of an outpatient respiratory physiotherapy protocol on hospitalization rates among infants up to 12 months of age diagnosed with mild to moderate acute viral bronchiolitis in the public healthcare system of Sorocaba, Brazil. Infants referred for respiratory physiotherapy will be compared with a similar group of infants who receive standard medical care without physiotherapy referral.\n\nThe physiotherapy protocol includes slow expiratory techniques, rhinopharyngeal retrograde clearance, cough stimulation, and continuous positive airway pressure (CPAP) when clinically indicated. Participants will be followed through medical records and telephone monitoring.\n\nThe primary outcome is hospital admission due to bronchiolitis. Secondary outcomes include length of hospital stay, healthcare costs, and clinical evolution. The findings may provide evidence on whether outpatient respiratory physiotherapy can reduce hospitalizations and optimize healthcare resource utilization in infants with acute viral bronchiolitis.",[278],"Acute Viral Bronchiolitis",[280,281,282,283,284,285,286],"Child","Bronchiolitis","SUS","Hospitalization","Respiratory Therapy","Ambulatory Care","Public Health","2026-06-30",{"date":289,"type":31},"2026-07-06",{"date":198,"type":22},{"date":292,"type":22},"2027-12",{"name":37,"class":38},{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":18,"minAge":301,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":50,"phases":304,"briefSummary":306,"conditions":307,"keywords":311,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":39},"100602205","phase-4-esketamine-versus-crisis-response-planning-versus-optimized-treatment-as-usual-for-suicide-prevention-a-pragmatic-controlled-trial-in-two-brazilian-cities-100602205","NCT07120477","Esketamine Versus Crisis Response Planning Versus Optimized Treatment as Usual for Suicide Prevention: A Pragmatic Controlled Trial in Two Brazilian Cities","SAVE","Inclusion Criteria:\n\n1. Age 14 years or older\n2. Presentation to a public emergency service (ED\u002FUEU) within the study municipality\n3. Recent suicide attempt within the past 30 days (actual, interrupted, or aborted attempt)\n4. Current severe suicidal ideation, defined as endorsement of items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) screening version, indicating active suicidal ideation with specific plan and\u002For method, or active suicidal ideation with intent to act\n5. Residency in the catchment area of the study municipality (Indaiatuba, São Paulo, Brazil), enabling completion of follow-up assessments\n6. Ability to provide written informed consent (for participants aged 18 years or older) or written assent with written informed consent from a parent or legal guardian (for participants aged 14-17 years)\n7. No clinical decision for involuntary or voluntary hospitalization in a psychiatric inpatient unit following the index emergency department evaluation\n\nExclusion Criteria:\n\n1. Contraindications to esketamine, including: aneurysmal vascular disease, arteriovenous malformation, history of intracerebral hemorrhage, or known hypersensitivity to esketamine or ketamine\n2. Current pregnancy or breastfeeding (confirmed by rapid pregnancy test in the emergency setting for female participants of childbearing potential)\n3. Medical instability requiring intensive care unit (ICU) admission without feasible study follow-up\n4. Primary psychotic disorder (e.g., schizophrenia, schizoaffective disorder), current acute psychosis, or current acute manic episode precluding informed participation\n5. Severe substance use disorder compromising capacity for treatment adherence, as assessed by the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)\n6. Inability to maintain contact for follow-up assessments, including participants whose residential address is located outside the study municipality","14 Years",{"count":303,"type":22},468,[305],"PHASE4","Suicide is one of the leading causes of early death worldwide. In Brazil, suicide rates have been rising steadily over the past two decades, and most suicides occur in low- and middle-income countries where access to specialized care is limited. There is an urgent need for fast-acting, practical interventions that can be delivered in public emergency settings. Two promising approaches have emerged: esketamine, a medication that can rapidly reduce suicidal thoughts within hours, and Crisis Response Planning (CRP), a brief session in which a trained clinician works with the person to create a personalized written plan for managing future suicidal crises.\n\nThe goal of this clinical trial is to learn if esketamine or Crisis Response Planning (CRP), each added to enhanced treatment as usual (eTAU), can prevent future suicide-related events compared to eTAU alone in adolescents and adults aged 14 years or older who recently attempted suicide or have severe suicidal thoughts. The main questions it aims to answer are:\n\nDoes a single esketamine infusion plus eTAU lower the risk of a new suicide-related event compared to eTAU alone over 12 months? Does a single session of Crisis Response Planning plus eTAU lower the risk of a new suicide-related event compared to eTAU alone over 12 months? Which approach leads to faster or more lasting improvements in suicidal thoughts, depression, anxiety, sleep, well-being, hopelessness, and quality of life? Are these interventions feasible, acceptable, and cost-effective within a public health system?\n\nResearchers will compare three groups to see which approach works best to prevent suicide attempts, suicide-related hospitalizations, and suicide deaths over one year.\n\nA total of 468 participants will be randomly assigned in equal numbers (156 per group) to one of three groups:\n\nEsketamine group: receive a single intravenous esketamine infusion (0.50 mg\u002Fkg given over 40 minutes) in a monitored medical setting with continuous heart rate, blood pressure, and oxygen monitoring, plus eTAU. A physician will be present throughout. Participants will be observed for up to 24 hours before discharge.\n\nCrisis Response Planning group: complete one 20-to-45-minute session with a trained clinician to build a personal crisis plan that includes warning signs, coping strategies, reasons for living, support contacts, and emergency resources. Participants will leave with a written and digital copy of their plan, plus eTAU.\n\nEnhanced treatment as usual (eTAU) group: receive standard emergency care, safety counseling about access to lethal means, connection to the local mental health network (including Psychosocial Care Centers and primary care), and a scheduled psychiatric follow-up appointment within 7 days.\n\nParticipants will:\n\nComplete health questionnaires about suicidal thoughts, depression, anxiety, sleep, well-being, hopelessness, and quality of life at 11 time points over one year (at enrollment, 24 hours, 7 days, 2 weeks, 4 weeks, 8 weeks, 16 weeks, 24 weeks, 32 weeks, 40 weeks, and 1 year) Provide a blood sample at the start of the study for exploratory analyses of biological markers that may be related to treatment response Use a smartphone app to report their mood, thoughts, and emotions four times a day for four weeks after enrollment Be monitored for safety and adverse events throughout the entire study period\n\nThe study takes place in the public emergency network of Indaiatuba, São Paulo, Brazil (population approximately 256,000), and is designed to reflect real-world clinical conditions. Participants who experience a new suicide-related event during the study will be offered an open-label rescue treatment combining esketamine and Crisis Response Planning, and will continue to be followed for the remainder of the year. The study also includes an evaluation of how well these interventions can be adopted and sustained within Brazil's public mental health system, including assessments of acceptability, feasibility, and cost-effectiveness.",[308,309,310],"Suicide Prevention","Ketamine","Crisis Response Plan",[308,309,310],"2026-06-28",{"date":287,"type":31},{"date":315,"type":31},"2026-06-01",{"date":317,"type":22},"2029-12",{"name":37,"class":38},{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":327,"enrollmentInfo":328,"targetDuration":4,"studyType":50,"phases":330,"briefSummary":331,"conditions":332,"keywords":335,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":39},"100625972","transcranial-alternating-current-stimulation-for-generalized-anxiety-disorder-and-insomnia-an-open-label-pilot-study-100625972","NCT07429578","Transcranial Alternating Current Stimulation for Generalized Anxiety Disorder and Insomnia: An Open-Label Pilot Study","Transcranial Alternating Current Stimulation for the Treatment of Anxiety and Insomnia: An Open-Label Pilot Clinical Trial","NewWaves","Inclusion Criteria:\n\nAge between 18 and 65 years; Diagnosis of Generalized Anxiety Disorder (GAD) based on Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria; Diagnosis of chronic primary insomnia; Hamilton Anxiety Rating Scale (HAM-A) score ≥15 at screening, indicating at least moderate anxiety severity; Score \\>5 on the Pittsburgh Sleep Quality Index (PSQI); Stable use of antidepressants (SSRI or SNRI) is allowed; Limited use of benzodiazepines (maximum of 10 mg\u002Fday diazepam equivalent).\n\nExclusion Criteria:\n\nHistory of mania, hypomania, or bipolar disorder; Contraindications to the use of transcranial stimulation; Active suicidal ideation or suicide attempt in the last 4 weeks; Refractoriness to 3 or more antidepressant treatments; Pregnancy; Other psychiatric diagnoses (e.g., schizophrenia, substance dependence, major depressive disorder); Severe medical or neurological conditions; Anxiety or insomnia secondary to other medical or psychiatric conditions (e.g., hypothyroidism, anemia).","65 Years",{"count":329,"type":22},30,[52],"This is an open-label pilot clinical trial to evaluate the effects of transcranial alternating current stimulation (tACS) in adults diagnosed with generalized anxiety disorder (GAD) and chronic primary insomnia. The study will involve 30 participants who will receive 20 sessions of tACS over four weeks. The stimulation will be delivered at 15 mA and 77.5 Hz using the Nexalin device. The main goal is to assess improvements in anxiety and sleep quality. Results from this study will provide preliminary evidence for future randomized controlled trials.",[333,334],"Generalized Anxiety Disorder (GAD)","Chronic Insomnia",[336,337,338,339,340,341,342],"tACS","Neuromodulation","Non-invasive brain stimulation","Sleep disorders","Anxiety treatment","Transcranial alternating current stimulation","Generalized Anxiety Disorder","2026-06-19",{"date":345,"type":31},"2026-06-23",{"date":347,"type":31},"2025-06-01",{"date":349,"type":22},"2026-07-31",{"name":37,"class":38},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":359,"enrollmentInfo":360,"targetDuration":4,"studyType":50,"phases":362,"briefSummary":363,"conditions":364,"keywords":365,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":385,"leadSponsor":387,"locationsCount":388},"100641214","phase-1-cd19-directed-car-t-cell-therapy-in-refractory-systemic-lupus-erythematosus-100641214","NCT07659704","CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus","CD19-targeted Lymphocyte Engineering Validation for the trEatment of Refractory Systemic Lupus Erythematosus","CLEVER-SLE","Inclusion Criteria:\n\n* Adults aged 18 to 50 years, inclusive.\n* Diagnosis of systemic lupus erythematosus (SLE) according to the 2019 ACR\u002FEULAR classification criteria.\n* Active disease at screening, defined as SLEDAI-2K ≥4 and Physician Global Assessment (PGA) ≥0.5.\n* Inadequate response, intolerance, or contraindication to corticosteroids and at least two of the following therapies: azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, belimumab, rituximab, or tacrolimus.\n* Adequate organ function, including:\n\n  * Hepatic function: AST and ALT ≤3× upper limit of normal (ULN); total bilirubin ≤2× ULN (participants with documented Gilbert syndrome are eligible).\n  * Hematologic function: neutrophils ≥1,000\u002Fmm³; hemoglobin ≥8 g\u002FdL without transfusion within 14 days; lymphocytes ≥500\u002Fmm³; platelets ≥20,000\u002Fmm³ without transfusion within 14 days.\n  * Renal function: estimated creatinine clearance ≥30 mL\u002Fmin (CKD-EPI).\n  * Cardiac function: left ventricular ejection fraction ≥40%.\n  * Pulmonary function: oxygen saturation ≥92% on room air.\n* Women of childbearing potential must agree to use highly effective contraception during study participation and for 12 months after CAR-T cell infusion.\n* Male participants must agree to use barrier contraception during study participation and for 12 months after CAR-T cell infusion.\n* Ability to understand and provide written informed consent.\n\nExclusion Criteria:\n\n* Severe pulmonary hypertension (estimated pulmonary artery systolic pressure \\>50 mmHg).\n* Requirement for systemic anticoagulation at screening.\n* Clinically significant cardiovascular disease, including NYHA Class III\u002FIV heart failure, myocardial infarction, unstable arrhythmias, or unstable angina within the previous 6 months.\n* Active neurological disease (stroke, epilepsy, or neurodegenerative disorders) within the previous 12 months.\n* History of malignancy within 2 years prior to screening, except for adequately treated non-melanoma skin cancer, cervical carcinoma in situ, localized prostate cancer, ductal carcinoma in situ of the breast, or stage I uterine cancer.\n* Previous or suspected hemophagocytic lymphohistiocytosis\u002Fmacrophage activation syndrome.\n* Active or uncontrolled bacterial, viral, fungal, or other infection.\n* Active hepatitis B infection or detectable HBV DNA.\n* Active hepatitis C infection or detectable HCV RNA.\n* Human immunodeficiency virus (HIV) infection.\n* Pregnancy, breastfeeding, or plans to become pregnant during the study or within 12 months after CAR-T cell infusion.\n* Major surgery within 4 weeks prior to screening.\n* Administration of a live attenuated vaccine within 4 weeks prior to screening.\n* Prior allogeneic or autologous hematopoietic stem cell transplantation or prior solid organ transplantation.\n* Inability or unwillingness to comply with study procedures and follow-up requirements.\n* Any medical condition that, in the investigator's judgment, could compromise participant safety or interfere with study assessments.","50 Years",{"count":361,"type":22},16,[81,82],"Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system mistakenly attacks the body's own tissues and organs. The disease can affect the skin, joints, kidneys, blood cells, brain, and other organs, leading to significant health problems and reduced quality of life. Although several treatments are available, some patients continue to have active disease despite receiving standard therapies.\n\nRecent research has shown that B cells, a type of immune cell, play a central role in the development and persistence of SLE. CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy is an innovative treatment that uses a patient's own immune cells, genetically modified to recognize and eliminate B cells. This approach has already shown remarkable success in certain blood cancers and has recently produced encouraging results in patients with severe autoimmune diseases, including SLE.\n\nThe CLEVER-SLE study is a Phase I\u002FII clinical trial designed to evaluate the safety and potential effectiveness of CD19-directed CAR-T cell therapy produced at Ribeirao Preto Blood Bank in patients with SLE who have not responded adequately to conventional treatments. Participants will undergo the collection of their own immune cells, which will be modified in a specialized laboratory to produce CAR-T cells. After receiving preparatory chemotherapy, participants will receive a single intravenous infusion of these CAR-T cells.\n\nThe main goal of this study is to evaluate the safety of this treatment. Researchers will also assess its effects on disease activity, symptoms, organ involvement, medication requirements, immune system markers, and the duration of clinical responses. The study aims to determine whether CD19-directed CAR-T cell therapy can provide a new treatment option for patients with refractory SLE and contribute to the development of CAR-T therapies for autoimmune diseases.",[193],[366,367,368,369,370,371,372,373,374,375,376,377,378,379,380],"Systemic Lupus Erythematosus","SLE","Refractory Systemic Lupus Erythematosus","Lupus Nephritis","CAR-T Cell Therapy","CD19-Directed CAR-T Cells","CD19","Chimeric Antigen Receptor T Cells","B Cell Depletion","B Lymphocytes","Autoimmune Diseases","Cellular Therapy","Advanced Therapy Medicinal Products","Immune Reconstitution","Autologous CAR-T Cells","2026-06-15",{"date":383,"type":31},"2026-06-22",{"date":175,"type":22},{"date":386,"type":22},"2028-10-01",{"name":37,"class":38},2,{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":397,"enrollmentInfo":398,"targetDuration":4,"studyType":50,"phases":400,"briefSummary":401,"conditions":402,"keywords":404,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":39},"100642546","phase-2-telerehabilitation-and-biomarkers-of-recovery-after-stroke-in-brazil-100642546","NCT07646522","Telerehabilitation and Biomarkers of Recovery After Stroke in Brazil","Telerehabilitation and Biomarkers of Functional Recovery After Stroke in Brazil: TR-BR-1 Clinical Trial","TR-BR-1","Inclusion Criteria:\n\n1. Age 18-80 years at the time of randomization.\n2. The index stroke was radiologically verified, due to ischemia, and had time of onset 120±30 days prior to randomization.\n3. The stroke caused upper extremity deficits as defined by Action Research.\n4. Arm Test score 18-44 (out of 57) at Baseline Visit.\n5. Box \\& Block Test score with affected arm is ≥1 block in 60 seconds at Baseline Visit.\n6. Able to successfully perform all 3 rehabilitation exercise test examples (simple commands) at Baseline Visit.\n7. Informed consent and behavioral contract signed by the subject (i.e., no surrogate consent).\n\nExclusion Criteria:\n\n1. A major, active, coexistent neurological, psychiatric, or medical disease that reduces the likelihood that a subject will be able to comply with all study procedures.\n2. Unable or unwilling to perform study procedures\u002Ftherapy, or expectation of noncompliance with study procedures\u002Ftherapy, or expectation that subject cannot participate in all study visits.\n3. A diagnosis (apart from the index stroke) that substantially affects paretic arm function.\n4. Severe depression, defined as Geriatric Depression Scale Score \\>10\u002F15 at Baseline Visit.\n5. Significant cognitive impairment, defined as Montreal Cognitive Assessment \\[a lower score can be permitted at the discretion of the PI\\].\n6. Deficits in communication that interfere with reasonable study participation.\n7. Severe UE spasticity, defined as presence of contracture or modified Ashworth Scale score=4 in either biceps or pectoralis.\n8. Modified Rankin Scale score \\>2 prior to the index stroke.\n9. A new symptomatic stroke has occurred since the index stroke, or a separate stroke occurred within 30 days prior to the index stroke.\n10. Lacking visual acuity, with or without corrective lens, of 20\u002F50 or better in at least one eye.\n11. Life expectancy \\\u003C 9 months\n12. Pregnancy; women of child-bearing potential must have a negative pregnancy test.\n13. Botulinum toxin to the paretic arm: received in the prior 3 months or expected by the 1-Month Visit.\n14. Concurrent enrollment in another therapy-based investigational study where the duration of the investigational therapy's activity is likely to occur during the subject's participation in the study.\n15. Subject lacks sufficient Portuguese to comply with study procedures and TR instructions.\n16. Contraindication to MRI.\n17. Contraindication to TMS.\n18. Box and Block Test score of ≥30 blocks with the unaffected arm within 60 seconds at Baseline Visit;\n19. Spatial neglect interfering with reasonable participation in the study;\n20. On isolation precautions, e.g., due to active COVID-19.\n21. Expectation that participant will not have a single domicile address during the 6 weeks of therapy.\n22. Distance from the participant's home to the study site greater than 120 km \\[this can be waived at the discretion of the PI\\].\n\n22\\. Availability of a 2 m² space for a table and chair setup.","80 Years",{"count":399,"type":22},20,[82],"The purpose of this research study is to provide preliminary evidence of whether telerehabilitation targeting arm movement, when added to usual care, improves arm function and reduces global disability after stroke, compared to usual care alone in Brazil. Evaluate the safety and feasibility of telerehabilitation in the Brazilian context. Explore the clinical, neuroimaging, neurophysiological, and economic factors that influence telerehabilitation efficacy in functional recovery following stroke.",[403],"Stroke",[405,406,407],"stroke","telerehabilitation","functional recovery","2026-06-13",{"date":410,"type":31},"2026-06-16",{"date":412,"type":31},"2026-06-12",{"date":414,"type":22},"2028-02-29",{"name":37,"class":38},{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":12,"sex":423,"minAge":19,"maxAge":4,"enrollmentInfo":424,"targetDuration":4,"studyType":50,"phases":426,"briefSummary":427,"conditions":428,"keywords":431,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":39},"100628550","creatine-supplementation-and-resistance-training-to-improve-sarcopenia-parameters-in-patients-with-prostate-cancer-after-androgen-deprivation-therapy-100628550","NCT07463092","Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy","The Effect of Creatine Supplementation Associated With Resistance Training on Sarcopenia Parameters and Muscle Density in Prostate Cancer Patients After Androgen Deprivation Therapy","Inclusion Criteria:\n\n* Men aged ≥ 40 years;\n* Patients with histologically or cytologically confirmed localized prostate cancer;\n* Patients who have undergone surgical castration or pharmacological castration with gonadotropin-releasing hormone (GnRH\u002FLHRH) agonists or antagonists for at least six months prior to the start of the intervention;\n* Patients receiving continuous or intermittent androgen deprivation therapy;\n* Patients with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;\n* Not engaged in resistance training in the three months prior to the intervention;\n* Not using creatine supplementation in the three months prior to the intervention;\n* Willing to participate in a 12-week intervention consisting of resistance training performed three times per week and daily supplementation with creatine monohydrate or maltodextrin.\n\nExclusion Criteria:\n\n* Patients with insulin-dependent diabetes mellitus;\n* Patients with dialysis-dependent renal failure;\n* Patients with severe chronic liver disease;\n* Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m²;\n* Any hormonal treatment outside that established by the medical team;\n* Patients planning to undergo chemotherapy within the next six months.","MALE",{"count":425,"type":22},34,[52],"This randomized, double-blind, placebo-controlled clinical trial will investigate the effects of creatine supplementation combined with a 12-week supervised resistance training program on muscle mass, muscle strength, physical performance (e.g., parameters of sarcopenia), and muscle density in men with prostate cancer undergoing androgen deprivation therapy (ADT). ADT often causes loss of lean mass, reduced muscle strength, functional impairment, and increased fat mass. Eligible male patients will be randomly assigned to receive either creatine monohydrate or a placebo (maltodextrin) in a double-blind manner, in addition to participating in the resistance exercise program. Assessments will be performed at baseline and after the 12-week intervention period and will include:\n\n* Muscle density and architecture assessed by ultrasound\n* Body composition (lean mass and fat mass)\n* Muscle strength\n* Physical performance (functional performance tests)\n* Inflammatory biomarkers\n* Vascular function parameters\n\nThe primary goal is to assess whether creatine supplementation combined with resistance training can safely improve muscle quality and quantity, strength, and physical function in these patients. If effective and safe, the intervention could help reduce muscle loss and improve quality of life in men undergoing ADT.",[429,430],"Prostate Cancer","Sarcopenia",[429,432,433,434,435,430],"Androgen Deprivation Therapy","Creatine","Resistance Training","Muscle Density","2026-06-10",{"date":438,"type":31},"2026-06-11",{"date":440,"type":31},"2026-05-01",{"date":442,"type":22},"2029-01",{"name":37,"class":38},{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":50,"phases":453,"briefSummary":454,"conditions":455,"keywords":456,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":465,"leadSponsor":467,"locationsCount":39},"100640776","volume-stable-collagen-matrix-versus-subepithelial-connective-tissue-graft-for-multiple-gingival-recessions-100640776","NCT07613775","Volume-Stable Collagen Matrix Versus Subepithelial Connective Tissue Graft for Multiple Gingival Recessions","Volume-Stable Xenogeneic Collagen Matrix Versus Subepithelial Connective Tissue Graft for the Treatment of Multiple Gingival Recessions: A 12-Month Randomized Controlled Clinical Trial","VCMX-SCTG","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Presence of at least two Cairo RT1 gingival recessions in anterior teeth and\u002For premolars.\n* Gingival recession depth greater than or equal to 2 mm.\n* Presence of at least 2 mm of keratinized gingiva apical to the gingival recession.\n* Indication for root coverage treatment due to esthetic concern and\u002For dentin hypersensitivity.\n* Sites with non-carious cervical lesions may be included if they are previously restored and, after restoration, present residual gingival recession greater than or equal to 2 mm.\n* Good plaque control, defined as full-mouth plaque score and full-mouth marginal gingival bleeding score below 20%.\n\nExclusion Criteria:\n\n* Current smokers or individuals who stopped smoking less than 12 months before enrollment.\n* Decompensated systemic diseases.\n* Pregnancy or lactation.\n* Active periodontal disease.\n* Untreated root caries.\n* Previous mucogingival surgery in the study area.",{"count":102,"type":22},[52],"Gingival recession is a clinical condition in which the gingival margin is displaced apically, exposing the root surface. This condition may be associated with esthetic concerns, dentin hypersensitivity, and difficulties in oral hygiene. Subepithelial connective tissue grafting is considered a standard surgical approach for root coverage, but it requires harvesting tissue from the palate, which may increase postoperative discomfort. Volume-stable xenogeneic collagen matrices have been proposed as an alternative biomaterial to reduce the need for a palatal donor site.\n\nThis randomized controlled clinical trial will compare a volume-stable xenogeneic collagen matrix with an autogenous subepithelial connective tissue graft for the treatment of multiple gingival recessions. Participants will be allocated to one of two treatment groups. The test group will receive root coverage surgery using a volume-stable collagen matrix, while the control group will receive root coverage surgery using a subepithelial connective tissue graft. Clinical, patient-reported, esthetic, and digital outcomes will be assessed at baseline and during follow-up visits up to 12 months.\n\nThe primary outcome will be the change in gingival recession depth from baseline to 12 months. Secondary outcomes will include keratinized tissue width, gingival thickness, percentage of root coverage, complete root coverage, dentin hypersensitivity, patient-reported satisfaction, early wound healing, and digital volumetric changes assessed by intraoral scanning.",[253],[457,458,459,460],"Multiple Gingival Recessions","Volume-Stable Collagen Matrix","Subepithelial Connective Tissue Graft","Coronally Advanced Flap","2026-05-30",{"date":463,"type":31},"2026-06-02",{"date":175,"type":22},{"date":466,"type":22},"2027-12-01",{"name":37,"class":38},{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":474,"eligibilityCriteria":475,"healthyVolunteers":17,"sex":18,"minAge":47,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":50,"phases":477,"briefSummary":478,"conditions":479,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":39},"100637864","development-of-a-sanitizing-tablet-for-removable-partial-dentures-100637864","NCT07608211","Development of a Sanitizing Tablet for Removable Partial Dentures","Development of a Denture Cleanser Tablet: Evaluation of Antibiofilm Activity and Effects on the Constituent Surfaces of Removable Partial Dentures.","DSRPD","Inclusion Criteria:\n\n* Participants aged 18 years or older.\n* Users of maxillary and\u002For mandibular removable partial dentures (RPD) made of acrylic resin.\n* Good systemic and oral health status, with enough healthy remaining teeth to support the RPD.\n* Agreement to follow the requested oral hygiene and denture cleaning protocols.\n* Ability to understand and sign the Informed Consent Form.\n\nExclusion Criteria:\n\n* Use of systemic antibiotics, antifungals, or anti-inflammatory drugs within the last 3 months.\n* History of allergic reactions to N-acetylcysteine (NAC), Melaleuca alternifolia (tea tree) oil, or components of the commercial positive control (NitrAdine).\n* Severe periodontal disease or extensive untreated caries in the remaining teeth.\n* Severe systemic diseases, immunodeficiency, or conditions that compromise manual dexterity to perform denture brushing.\n* Pregnant or lactating women.",{"count":79,"type":22},[52],"The goal of this clinical trial is to learn if a new experimental effervescent tablet works to clean removable partial dentures. It will test if the tablet lowers bacteria and fungi on denture surfaces. The main questions it aims to answer are: Does the experimental tablet lower the number of microbes on different denture materials? How happy are participants with the taste, odor, and cleanliness of the tablet? Researchers will compare the experimental tablet to a known commercial cleanser and to a neutral water solution to see which one works best. Total participation will last 70 days. First, researchers will place small material discs on the side of the participant's current denture to collect natural plaque. Participants will wear their dentures 24 hours a day and brush them with soap and water after meals. Participants will then cycle through three separate 14-day testing phases. In each phase, participants will soak their dentures daily for 15 minutes in one of the assigned solutions. Participants will also have a 7-day break between each phase where they return to their basic regular cleaning routine. At the end of each testing phase, researchers will remove the small discs to count the microbes in a laboratory. Participants will also answer a short survey about their satisfaction with each product.",[480],"Denture Stomatitis","2026-05-27",{"date":315,"type":31},{"date":484,"type":22},"2026-06-08",{"date":486,"type":22},"2027-12-30",{"name":37,"class":38},{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":495,"enrollmentInfo":496,"targetDuration":4,"studyType":50,"phases":498,"briefSummary":499,"conditions":500,"keywords":502,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":510,"leadSponsor":512,"locationsCount":4},"100640986","phase-4-vitamin-b-complex-for-inferior-alveolar-nerve-paresthesia-recovery-100640986","NCT07592897","Vitamin B Complex for Inferior Alveolar Nerve Paresthesia Recovery","Efficacy of Vitamin B Complex in the Recovery of Inferior Alveolar Nerve Paresthesia: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Clinical diagnosis of mandibular neurossensorial disturbances.\n* Must be able to swallow tablets\n\nExclusion Criteria:\n\n\\- Any known allergy to complex B supplementation or its components.","70 Years",{"count":497,"type":22},50,[305],"Why is this study being done? Paresthesia is a change in sensation that can cause numbness, tingling, or loss of feeling in a part of the body. This condition can occur after dental procedures such as wisdom tooth (third molar) extraction, dental implant placement, or jaw surgery. When this happens, the inferior alveolar nerve - which is responsible for sensation in the lower lip, chin, and gum area on the side of the jaw - may be injured. This can affect a person's quality of life, making everyday activities like eating, drinking, speaking, and even smiling feel different or uncomfortable.\n\nWhat is being studied? This study is testing whether taking B vitamins (vitamin B complex) can help the inferior alveolar nerve recover faster and more completely compared to a placebo (an inactive pill that looks the same but contains no active medicine). B vitamins - especially B1 (thiamine), B6 (pyridoxine), and B12 (cyanocobalamin) - are known to play important roles in nerve health, including helping repair damaged nerves and maintaining the protective covering around nerves called myelin.\n\nWho can participate? Adults between 18 and 70 years old who have numbness or altered sensation in the lower lip, chin, or gum area caused by damage to the inferior alveolar nerve following a dental procedure (specifically wisdom tooth extraction), and whose symptoms began between 7 and 30 days ago.\n\nWhat will happen in the study?\n\nParticipants will be randomly assigned (like flipping a coin) to one of two groups:\n\nVitamin B complex group: Takes one capsule daily containing B vitamins\n\nPlacebo group: Takes one identical-looking capsule daily with no active ingredients\n\nNeither the participants nor the doctors performing the sensory tests will know which group they are in. This is called a \"blinded\" study and helps ensure the results are reliable.\n\nParticipants will attend 6 scheduled visits over 8 weeks:\n\nT0 (baseline): Initial sensory testing, questionnaires, and receiving the study medication\n\nT1 (1 week): Follow-up sensory testing\n\nT2 (2 weeks): Follow-up sensory testing\n\nT3 (4 weeks): Follow-up sensory testing\n\nT4 (6 weeks): Follow-up sensory testing\n\nT5 (8 weeks): Final sensory testing and end of study participation\n\nAt each visit, researchers will perform simple, non-invasive tests to measure sensation in the affected area, including:\n\nLight touch tests with soft nylon filaments (monofilaments)\n\nTwo-point discrimination (testing the ability to feel one or two points touching the skin)\n\nPinprick sensation (testing sharp touch)\n\nTemperature sensation (warm and cold)\n\nVisual Analog Scale (VAS) where participants rate their sensation on a scale\n\nWhat are the possible benefits? Participants who receive the vitamin B complex may experience faster or more complete recovery of sensation in their lower lip, chin, or gum area. Even those in the placebo group may experience some improvement due to the body's natural healing process. All participants will receive close monitoring of their nerve function over 8 weeks.\n\nWhat are the possible risks? The risks are considered low. B vitamins are generally safe at the doses used in this study. Some people may experience mild side effects such as nausea or stomach discomfort. Rarely, allergic reactions may occur. The sensory tests may cause mild, temporary discomfort but no pain. If any side effects occur, the study medication will be stopped and appropriate care will be provided.\n\nIs participation voluntary? Yes. Participants can withdraw from the study at any time without any impact on their regular dental or medical care.\n\nWhere will the study take place? The study will be conducted at the Faculdade de Odontologia da Universidade de São Paulo (FOUSP) and the Fundação para o Desenvolvimento da Odontologia (FUNDECTO).",[501],"Paresthesia and Hypoesthesia",[503,504,505],"paresthesia","third molar","surgery, oral","2026-05-18",{"date":508,"type":31},"2026-05-20",{"date":436,"type":22},{"date":511,"type":22},"2028-06-10",{"name":37,"class":38},{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":18,"minAge":521,"maxAge":522,"enrollmentInfo":523,"targetDuration":4,"studyType":50,"phases":525,"briefSummary":527,"conditions":528,"keywords":539,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":556,"leadSponsor":558,"locationsCount":4},"100634665","early-phase-1-chloramphenicol-tetracycline-zinc-oxide-and-eugenol-paste-ctz-paste-for-emergency-dental-treatment-in-public-health-settings-a-randomized-trial-100634665","NCT07542639","Chloramphenicol, Tetracycline, Zinc Oxide and Eugenol Paste (CTZ Paste) for Emergency Dental Treatment in Public Health Settings: A Randomized Trial","Clinical and Radiographic Efficacy of Chloramphenicol, Tetracycline, Zinc Oxide and Eugenol Paste (CTZ Paste) in the Context of Emergency Dental Treatments in Brazilian Public Health: Randomized Clinical Trial","CTZ- emergency","Inclusion Criteria:\n\n* Pediatric patients presenting with:\n* Irreversible pulpitis in primary molars;\n* Pulp necrosis, with or without abscess, in primary molars.\n* Primary molars with sufficient remaining tooth structure to allow endodontic treatment.\n* Primary teeth in which the permanent successor tooth germ presents developmental stages compatible with Nolla stages 1 to 7, defined as:\n\nStage 1: Presence of bony crypt with no evidence of calcification; Stage 2: Initial calcification, with appearance of radiopaque points in the crown region; Stage 3: Approximately one-third of crown formation; Stage 4: Approximately two-thirds of crown formation; Stage 5: Crown almost complete, without full calcification; Stage 6: Crown completely formed, without initiation of root formation; Stage 7: Initial root formation.\n\n* Clinical and radiographic conditions indicating feasibility of tooth maintenance through endodontic treatment, including:\n* Permanent successor in developmental stages prior to Nolla Stage 8;\n* Preservation of the bony crypt.\n\nExclusion Criteria:\n\n* Pediatric patients presenting with:\n* Reversible pulpitis;\n* Indication for endodontic treatment in permanent teeth.\n* History of allergy or hypersensitivity to any components of the obturation materials (e.g., CTZ paste or zinc oxide-eugenol).\n* Clinical conditions that prevent adequate management in an outpatient setting.\n* Primary teeth in which the permanent successor:\n* Is in advanced developmental stages (Nolla Stage 8 or higher), and\u002For\n* Presents disruption of the bony crypt, contraindicating endodontic treatment.\n* Teeth presenting internal root resorption that compromises the feasibility of endodontic treatment.","2 Years","11 Years",{"count":524,"type":22},110,[526],"EARLY_PHASE1","The treatment of pulpal diseases in primary teeth represents a significant challenge in public health, particularly in emergency dental care settings, where factors such as limited clinical time, low child cooperation, and structural constraints directly impact treatment effectiveness. In these contexts, conventional pulpectomy using zinc oxide-eugenol (ZOE), although effective, may present operational limitations that restrict its large-scale applicability in public health systems.\n\nIn this scenario, non-instrumental endodontic treatment (NIET), based on the concept of Lesion Sterilization and Tissue Repair (LSTR), has emerged as a simplified alternative. Among the available options, CTZ paste shows potential for single-visit application, reducing clinical time and technical complexity.\n\nThis study aims to evaluate the clinical and radiographic non-inferiority of CTZ paste compared to conventional pulpectomy with ZOE in primary molars with pulp necrosis, with or without abscess or fistula, treated in emergency dental care settings.\n\nThis is a randomized, pragmatic, controlled, non-inferiority clinical trial conducted at a single center, with clinical and radiographic follow-up at 3, 6, and 12 months. Participants will be allocated into two groups: (1) NIET with CTZ paste and (2) conventional pulpectomy with ZOE.\n\nPrimary outcomes include pain resolution and absence of clinical signs of infection. Secondary outcomes include radiographic success, clinical time, child behavior (Frankl Scale), need for retreatment, and oral health-related quality of life.\n\nThe findings are expected to provide robust evidence regarding the effectiveness of CTZ paste under real-world clinical conditions, contributing to the development of more accessible and effective protocols within public health systems, with the potential to expand access to conservative treatment and reduce early tooth extractions in pediatric dentistry.",[529,530,531,532,533,534,535,536,537,538],"Pulp Disease, Dental","Pulp Necrosis","Pulp Therapy in Primary Molars","Primary Teeth","Pulpectomy","Endodontics","Dental Care for Children","Treatment Outcome","Quality of Life","Health Services Accessibility",[540,541,542,543,544,545,546,547,548,549,550,551],"pulpectomy","pulpotomy","CTZ paste","NIET","Non-instrumental endodontic treatment","LSTR","Lesion sterilization and tissue repair","Endodontic infection","dental abscess","Fistula","Emergency dental treatment","Public health dentistry","2026-05-07",{"date":554,"type":31},"2026-05-12",{"date":484,"type":22},{"date":557,"type":22},"2028-02-28",{"name":37,"class":38},{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":77,"enrollmentInfo":565,"targetDuration":4,"studyType":50,"phases":567,"briefSummary":569,"conditions":570,"keywords":573,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":4},"100639344","phase-3-brief-cognitive-behavioral-therapy-for-suicide-prevention-in-a-brazilian-sample-a-study-protocol-of-a-randomized-clinical-trial-100639344","NCT07574658","Brief Cognitive Behavioral Therapy for Suicide Prevention in a Brazilian Sample: a Study Protocol of a Randomized Clinical Trial","Study participants meet inclusion criteria if they are (1) Between the ages of 18-65; (2) Treatment-seeking status in outpatient mental health and\u002F or inpatient psychiatry discharge; (3) Report current (within the past week) suicide ideation (e.g., score greater than 2 on the Scale for Suicide Ideation) and\u002For a suicide attempt within the past month (e.g., as assessed by the Beck Scale for Suicide Ideation (BSI); (4) Able to understand and speak Portuguese; (5) Able to complete the informed consent process.",{"count":566,"type":22},150,[568],"PHASE3","The vast majority of suicides occur in low-and middle-income countries (LMICs), and evidence on effective psychotherapeutic interventions to prevent suicide that are culturally adapted to these contexts is limited. This scenario implies an urgent need for evidence-based suicide prevention strategies in Brazil. This research aims to evaluate the effectiveness of brief cognitive-behavioral therapy in preventing suicide in an outpatient setting of a Brazilian university. A randomized, controlled clinical trial with two arms, whose participants are adults who have attempted suicide or have had suicidal ideation with intent to die, will be designed. Inclusion criteria will be suicidal ideation with intent to die in the last week and\u002For suicide attempt in the last month. Patients will be randomly assigned to receive either a weekly 12-session supportive therapy or brief cognitive-behavioral therapy. The duration of treatment will be approximately 3 months. Both groups will have weekly individual therapy. Follow-up contact will be made 1 month and 6 months after treatment. If necessary, patients are entitled to two booster sessions during the follow-up period. The outcomes to be assessed, a priori, are suicide attempts, self-harm without suicidal intent and suicidal ideation, assessed by the Beck Scale for Suicide Ideation (BSI). Linear mixed models will be used to assess the outcomes of continuous variables, logistic regression models for categorical outcomes and survival analysis for the analysis of suicide attempts.",[571,572],"Suicide Ideation","Suicide Attempts",[574,575,576,577,578,579],"Suicide","Suicide prevention","Brief Cognitive Behavioral Therapy (BCBT)","Randomized clinical trial","Evidence-based psychotherapy","Low- and middle-income countries (LMICs)","2026-05-04",{"date":582,"type":31},"2026-05-08",{"date":584,"type":22},"2026-05-10",{"date":586,"type":22},"2028-07-10",{"name":37,"class":38},{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":593,"acronym":4,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":18,"minAge":595,"maxAge":495,"enrollmentInfo":596,"targetDuration":4,"studyType":50,"phases":597,"briefSummary":598,"conditions":599,"keywords":601,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":607,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":39},"100316407","early-immunosuppressive-therapy-on-the-course-of-vogt-koyanagi-harada-disease-100316407","NCT03399175","Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease","Influência de imunomodulação Precoce Influence of Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease: a Prospective Study","Inclusion criteria:\n\n\\- acute Vogt-Koyanagi-Harada disease\n\nExclusion criteria:\n\n* non collaborative patient\n* minimum one-year follow-up","10 Years",{"count":102,"type":22},[52],"This prospective study will include patients with Vogt-Koyanagi-Harada disease from disease onset, treated with early systemic high-dose corticosteroid and immunosuppressive therapy. Clinical and subclinical signs of disease activity added with electroretinogram exams, through predefined intervals, will be evaluated through a minimum 12-month follow-up.",[600],"Vogt Koyanagi Harada Disease",[602,603,604,605,606],"Vogt-Koyanagi-Harada disease","Immunosuppressive therapy","Indocyanine green angiography","Enhanced depth imaging optical coherence tomography","Electroretinogram",{"date":552,"type":31},{"date":609,"type":31},"2015-03-23",{"date":611,"type":22},"2028-12",{"name":37,"class":38},{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":4,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":155,"minAge":47,"maxAge":620,"enrollmentInfo":621,"targetDuration":4,"studyType":50,"phases":623,"briefSummary":624,"conditions":625,"keywords":638,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":659,"lastUpdatePostDateStruct":660,"startDateStruct":662,"completionDateStruct":664,"leadSponsor":666,"locationsCount":39},"100571149","aerobic-exercise-and-its-impact-on-sensory-musculoskeletal-and-psychosocial-aspects-in-migraine-100571149","NCT06716489","Aerobic Exercise and Its Impact on Sensory, Musculoskeletal, and Psychosocial Aspects in Migraine","Influence of Aerobic Exercise on Sensory Perception, Musculoskeletal and Psychosocial Alterations in Patients With Migraine","Inclusion Criteria:\n\n* Women aged between 18 and 48 years.\n* Diagnosed with migraine by an experienced neurologist specialized in headaches, following the criteria of the International Classification of Headache Disorders (ICHD).\n* Frequency of headache between 3 and 8 days per month, to ensure adherence to the treatment.\n\nExclusion Criteria:\n\n* Presence of any other type of concurrent headache.\n* Medical conditions affecting sensitivity and autonomic modulation, such as peripheral neuropathies, autonomic disorders, severe neurological diseases, and others.\n* Conditions that prevent physical activity, such as severe musculoskeletal injuries, cardiovascular diseases, or related conditions.\n* Premature ovarian failure.\n* Regular physical exercise in the past year.\n* Body Mass Index (BMI) above 30.0.\n* Smokers or individuals using drugs that interfere with sensitivity and cardiac modulation (e.g., beta-blockers).\n* Abuse of abortive medications.","48 Years",{"count":622,"type":22},100,[52],"Migraine is a neurological disorder associated with high levels of disability and changes in sensory processing, musculoskeletal function, and psychosocial factors. Aerobic exercise is a low-cost, non-pharmacological strategy that has shown potential benefits for migraine management, but its effects on sensory perception and musculoskeletal function are not yet fully understood.\n\nThis randomized controlled trial will investigate the effects of a supervised aerobic exercise program combined with pain neuroscience education compared with an active control condition in women aged 18 to 48 years diagnosed with migraine. Participants will be randomly allocated to either an intervention group, which will perform supervised aerobic exercise three times per week for 16 weeks and receive one session of pain neuroscience education, or a control group, which will receive recommendations for unsupervised physical activity at home.\n\nOutcomes related to migraine-related disability, self-reported symptoms, sensory sensitivity, and musculoskeletal function will be assessed at baseline and after the intervention period. Questionnaires will also be collected at a 6-month follow-up. The results of this study may contribute to the development of accessible and low-risk non-pharmacological treatment strategies for people with migraine.",[626,627,628,629,630,631,632,633,634,635,636,637,537],"Migraine","Migraine Disease","Migraine Disorder","Migraine Disorders, Brain","Headache","Headache (Migraine)","Headache Disorders","Headache Disorders, Primary","Aerobic Exercise","Pain Management","Sensory Disorders","Psychosocial Factors",[639,640,641,642,643,644,645,646,647,648,649,637,650,651,652,653,654,655,656,657,658],"migraine","aerobic exercise","sensory perception","exercise","headache","disability","musculoeskeletal alterations","quality of life","neck pain","cervical pain","Sensory Thresholds","Physical Fitness","Exercise Intervention","Central Sensitization","Physical Therapy","Migraine Management","Non-pharmacological Treatment","Clinical Trial","Headache Relief","sensitization","2026-04-27",{"date":661,"type":31},"2026-04-28",{"date":663,"type":31},"2026-03-03",{"date":665,"type":22},"2028-11-30",{"name":37,"class":38},{"id":668,"slug":669,"hasResults":12,"nctId":670,"briefTitle":671,"officialTitle":672,"acronym":4,"eligibilityCriteria":673,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":495,"enrollmentInfo":674,"targetDuration":4,"studyType":50,"phases":676,"briefSummary":677,"conditions":678,"keywords":681,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":659,"lastUpdatePostDateStruct":684,"startDateStruct":685,"completionDateStruct":687,"leadSponsor":689,"locationsCount":39},"100521754","effects-of-adjunct-antimicrobial-photodynamic-therapy-in-periodontal-treatment-of-patients-with-obesity-100521754","NCT06073704","Effects of Adjunct Antimicrobial Photodynamic Therapy in Periodontal Treatment of Patients With Obesity","Effects of Antimicrobial Photodynamic Therapy in Non-surgical Periodontal Treatment of Patients With Obesity","Inclusion Criteria:\n\n* Obesity (grade II and III classified according to Body Mass Index)\n* Periodontitis stage II to IV\n* Presence of at least 20 teeth excluding 3rd molars.\n\nExclusion Criteria:\n\n* Smokers\n* Alcohol or drugs consumption\n* Kidney disorders\n* Pregnancy or lactation\n* Use of antibiotics at the last 30 days\n* Use of drugs that alter periodontal structures as phenytoin or ciclosporin\n* Periodontal treatment at the last 6 months",{"count":675,"type":22},24,[52],"The goal of this clinical trial is to compare the effects of adjuvant antimicrobial photodynamic therapy (aPDT) as an adjuvant of scaling and root planing with scaling and root planing alone for periodontal treatment in patients with periodontal disease and obesity. The main question it aims to answer are: Does adjuvant aPDT improves periodontal health? Are there differences in the proteomic profile of gingival fluid after both treatments? Participants will receive scaling and root planing complemented or not by aPDT. Results will be collected after 1, 3, and 6 months. Researchers will compare adjuvant aPDT treatment to regular treatment to see if it promotes reduction in inflammation and improvement in periodontal health.",[679,680],"Periodontitis","Obesity",[682,683],"periodontitis","obesity",{"date":580,"type":31},{"date":686,"type":31},"2023-10-09",{"date":688,"type":22},"2026-12-30",{"name":37,"class":38},{"id":691,"slug":692,"hasResults":12,"nctId":693,"briefTitle":694,"officialTitle":694,"acronym":695,"eligibilityCriteria":696,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":4,"enrollmentInfo":697,"targetDuration":4,"studyType":50,"phases":699,"briefSummary":700,"conditions":701,"keywords":703,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":708,"lastUpdatePostDateStruct":709,"startDateStruct":711,"completionDateStruct":713,"leadSponsor":715,"locationsCount":4},"100635086","effects-of-intensive-glycemic-control-in-the-postoperative-period-of-neurosurgical-patients-on-the-incidence-of-surgical-site-infection-100635086","NCT07548112","Effects of Intensive Glycemic Control in the Postoperative Period of Neurosurgical Patients on the Incidence of Surgical Site Infection","Brain Sugar","Inclusion Criteria\n\n* Adults aged ≥18 years\n* Patients undergoing elective cranial neurosurgical procedures classified as clean surgeries\n\nExclusion Criteria:\n\n* Patients who underwent any surgical or neurosurgical procedure within 30 days prior to enrollment\n* Presence of active infection at any site\n* Patients undergoing emergency or urgent neurosurgical procedures\n* Patients with trauma and exposed brain tissue\n* Diagnosis of diabetic ketoacidosis\n* Blood glucose levels \\>600 mg\u002FdL",{"count":698,"type":22},572,[52],"Surgical site infections (SSIs) are frequent complications in neurosurgical patients, often worsened by perioperative hyperglycemia. This randomized, controlled trial will compare intensive glycemic control (continuous insulin infusion, 140-180 mg\u002FdL) with standard care (subcutaneous insulin, 81-180 mg\u002FdL) in 544 patients. The primary outcome is SSI occurrence within 90 days post-surgery. Results aim to guide optimal glycemic management for SSI prevention in neurosurgery.",[702],"Surgical Site Infection (SSI)",[704,705,706,707],"Nursing","Surgical Site Infection","Neurosurgery","Glycemic Control","2026-04-20",{"date":710,"type":31},"2026-04-23",{"date":712,"type":22},"2026-04-05",{"date":714,"type":22},"2027-10",{"name":37,"class":38},{"id":717,"slug":718,"hasResults":12,"nctId":719,"briefTitle":720,"officialTitle":721,"acronym":722,"eligibilityCriteria":723,"healthyVolunteers":12,"sex":155,"minAge":47,"maxAge":19,"enrollmentInfo":724,"targetDuration":4,"studyType":50,"phases":726,"briefSummary":727,"conditions":728,"keywords":731,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":736,"lastUpdatePostDateStruct":737,"startDateStruct":739,"completionDateStruct":740,"leadSponsor":741,"locationsCount":388},"100545889","acute-beetroot-juice-supplementation-in-pre-eclampsia-pregnancies-100545889","NCT06387784","Acute Beetroot Juice Supplementation in Pre-eclampsia Pregnancies","Acute Effect of Beetroot Juice Supplementation in Pregnant Women With Pre-eclampsia: a Single-Blind Randomized Placebo-Controlled Trial","BEET_PE","1. Pre-eclampsia pregnat women\n\n   Inclusion Criteria:\n   * Pregnant women at or beyond the 20th week of gestation.\n   * Hospitalized at Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto.\n   * Diagnosed with early-onset pre-eclampsia confirmed by a medical professional.\n   * Capacity to provide written informed consent for study participation.\n\n   Exclusion Criteria:\n   * Multiple pregnancies.\n   * Uncontrolled arterial hypertension (Systolic Blood Pressure \\> 160 mmHg or Diastolic Blood Pressure \\> 100 mmHg).\n   * Pregnant women with a body mass index \\> 40 kg\u002Fm²\n   * Severe gestational complications.\n   * History of food allergy with hypersensitivity to beetroot.\n   * Smokers.\n   * Chronic alcohol consumption.\n   * Medications such as non-steroidal anti-inflammatory drugs, nasal decongestants, users of proton pump inhibitors and H2 receptor antagonists or any other medication that interferes with stomach pH.\n   * Diagnosis of renal or hepatic disease affecting nitrate metabolism.\n   * Cardiac conditions such as moderate to severe congestive heart failure and coronary artery disease.\n   * Pre-existing type 1 or type 2 diabetes.\n2. Healthy Pregnant Women\n\nInclusion Criteria:\n\n* Healthy pregnant women at or beyond the 20th week of gestation.\n* Absence of pre-eclampsia diagnosis or other obstetric complications.\n* Willingness and ability to remain admitted at the Clinical Research Unit for the - period required by the study.\n* Capacity to provide written informed consent for study participation.\n\nExclusion Criteria:\n\n\\- The same exclusion criteria from Pre-eclampsia group apply.",{"count":725,"type":22},60,[52],"Pre-eclampsia is a serious condition that typically affects pregnant women after the 20th week of pregnancy, characterized by high blood pressure and damage to organs such as the kidneys and liver. Currently, treatment options are limited, which has prompted researchers to explore alternative approaches. One such promising alternative is dietary nitrate found in vegetables like beetroot, as nitrate can be converted into nitric oxide in the body, which helps lower blood pressure. This study aims to determine the acute effects of nitrate-rich beetroot juice on blood pressure, several blood and salivary markers in pregnant women with pre-eclampsia and healthy pregnant. Furthermore, the study will assess fetal blood flow using Doppler ultrasound. We want to understand the kinetics of nitrate and nitric oxide metabolites and assess the temporal dependency of the hypotensive response. Through this investigation, we seek evidence of nitrate-enriched beetroot juice as an adjunct therapy in managing pre-eclampsia.",[729,730],"Pre-Eclampsia","Pregnacy",[732,733,734,735],"Pre-eclampsia","Pregnancy","Beetroot Juice","Nitric Oxide","2026-04-15",{"date":738,"type":31},"2026-04-21",{"date":506,"type":22},{"date":200,"type":22},{"name":37,"class":38},""]